NIH readies $248M program for electroceuticals

Nature reports that the NIH will soon unveil a $248 million program to develop new 'electroceuticals,' therapeutic implants that can treat disease by stimulating nerves. "The nervous system is criss-crossing our viscera to control many aspects of our organ function," GlaxoSmitheKline's ($GSK) Kristoffer Famm tells Nature. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.